Risk of being admitted for non-cancer conditions is 38% higher in the year after a PCa diagnosis compared with a year before.
Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.
The advice is useful as clinicians wait for formal guidelines.
Ablating only the prostate lobe with the tumor resulted in satisfactory mid-term functional outcomes, researchers reported.
Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.
Patient age and tumor risk may be more strongly associated with use of expectant management for veterans with low-risk prostate cancer.
Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.
Antibiotics selected based on results of pre-biopsy rectal swab cultures.
Combination angiogenesis inhibition can be safely administered with supportive measures in metastatic castration-resistant prostate cancer (mCRPC).
Combined radiotherapy remains controversial due to the increased potential for toxicities.
Any baldness is associated with a 56% higher risk of dying from the malignancy.
Rate of unnecessary screening was 15.7% in men 65 years and older.
Many men are unaware of erectile function recovery time and problems with ejaculation.
Modified technique improved stress urinary incontinence in nearly three-quarters of patients.
Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.
Enzalutamide reduced the risk of disease progression by 56% in mCRPC patients.
A newly developed profiling method may be helpful in the management of patients with high-risk prostate cancer.
Estimated 33% of overall risk is genetic; certain types of cancer have additional risk.
The addition of zoledronic acid and celecoxib increases survival for men with hormone therapy-naïve metastatic prostate cancer.
Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.
Through diet and exercise, prostate cancer patients can decrease their risk of dying from their illness.
Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.
Patients with higher heterogeneity score did not respond well to hormone therapy.
Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs.
Second round of 6 injections was well tolerated and continued to control disease progression in bone.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Researchers observed a trend toward longer time on drug among men with castration-resistant prostate cancer.
In large observational study, regular use—defined as 3 tablets per week—was associated with a 24% lower risk of dying from prostate cancer.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
No significant association found between phosphodiesterase type 5 inhibitor use and biochemical recurrence after radical treatment.
- Twice-Weekly Dialysis May Preserve Residual Kidney Function
- Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible
- How to Prevent Sexual Transmission of Zika Virus
- Parathyroidectomy Cuts Mortality Risk in Patients With Severe SHPT
- Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)